N-acetylcysteine in the prevention of contrast-induced nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 281-287

  Fishbane, Steven ^a,b,c  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; SCAVENGER;

ACUTE KIDNEY FAILURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; HUMAN; REVIEW;

ACETYLCYSTEINE; CONTRAST MEDIA; FREE RADICAL SCAVENGERS; HUMANS; KIDNEY FAILURE, ACUTE;

EID: 38749139299     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02590607     Document Type: Article

References (80)

1. Arend LJ, Bakris GL, Burnett JC, Mergerian C, Spielman WS: Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 110: 406-411, 1987
2. Katzberg RW, Schulman G, Meggs LG, Caldicot WJH, Damieno MM, Hollenberg NK: Mechanism of renal response to contrast medium in dogs: Decrease in renal function due to hypertonicity. Invest Radiol 18: 74-80, 1983
3. Larson JS, Hudson K, Mertz JI, Romero JC, Knox FG: Renal vasoconstrictive response to contrast medium: The role of sodium balance and the renin-angiotensin system. J Lab Clin Med 101: 385-391, 1983
4. Schick CS, Haller C: Comparative cytotoxicity of ionic and non-ionic radiocontrast agents on MDCK cell monolayers in vitro. Nephrol Dial Transplant 14: 342-347, 1999
5. Talner LB, Davidson AJ: Renal hemodynamic effects of contrast media. Invest Radiol 3: 310-317, 1968
6. Nygren A: Contrast media and regional renal blood flow: A study of the effects of ionic and non-ionic monomeric and dimeric contrast media in the rat. Acta Radiol 378: 123-135, 1992
7. Humes HD, Hunt DA, White MD: Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells. Am J Physiol 252: F246-F255, 1987
8. Messana JM, Cieslinski DA, Nguyen VD, Humes HD: Comparison of the toxicity of the radiocontrast agents, iopamidol and diatrizoate, to rabbit renal proximal tubule cells in vitro. J Pharmacol Exp Ther 244: 1139-1144, 1988
9. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr: Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals. Am J Physiol 258: F115-F120, 1990
10. Yoshioka T, Fogo A, Becman JK: Reduced activity of anti-oxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 41: 1008-1015, 1992
11. Parvez Z, Rahman Ma, Moncada R: Contrast media-induced renal injury in volume depletion. Invest Radiol 24: 697-702, 1989
12. Zager RA, Johnson AC, Hanson SY: Radiographic contrast media-induced tubular injury: Evaluation of oxidant stress and plasma membrane integrity, Kidney Int 64: 128-139, 2003
13. Beeri R, Symon Z, Brezis M, Ben-Sasson SA, Baehr PH, Rosen S, Zager RA: Rapid DNA fragmentation from hypoxia along the thick ascending limb of rat kidneys. Kid Int 47: 1806-1810, 1995
14. Lieberman J: The appropriate use of mucolytic agents. Am J Med 49: 1-4, 1970
15. Sheffner AL: The mucolytic action of acetylcysteine. Tuberculol Thorac Dis 23: 31-33, 1966
16. Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT: Intravenous N-acetylcystine: The treatment of choice for paracetamol poisoning. BMJ 2: 1097-1100, 1979
17. Yip L, Dart RC: A 20-hour treatment for acute acetaminophen overdose. N Engl J Med 348: 2471-2472, 2003
18. Breen KJ, Bury RW, Desmond PV, Forge BH, Mashford ML, Whelan G: Paracetamol self-poisoning: diagnosis, management, and outcome. Med J Aust 1: 77-79, 1982
19. Dahlin DC, Nelson SD: Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen. J Med Chem 25: 885-886, 1982
20. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brody BB: Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 187: 211-217, 1973
21. Lauterburg BH, Corcoran GB, Mitchell JR: Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest 71: 980-991, 1983
22. Corcoran GB, Wong BK: Role of glutathione in prevention of acetaminophen-induced hepatotoxicity by N-acetyl-L-cysteine in vivo: Studies with N-acetyl-D-cysteine in mice. J Pharmacol Exp Ther 238: 54-61, 1986
23. Moldeus P, Cotgreave IA: N-acetylcysteine. Methods Enzymol 234: 482-492, 1994
24. Harada D, Naito S, Hiraoka I, Otagiri M: In vivo kinetic analysis of covalent binding between N-acetyl-L-cysteine and plasma protein through the formation of mixed disulfide in rats. Pharm Res 19: 615-620, 2002
25. Olsson B, Johansson M, Gabrielsson J, Bolme P: Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34: 77-82, 1988
26. Borgstrom. L, Kagedal B, Paulsen O: Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31: 217-222, 1986.
27. Bridgeman MM, Marsden M, MacNee W, Flenley DC, Ryle AP: Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 46: 39-42, 1991
28. Tsikas D, Sandmann J, Ikic M, Fauler J, Stichtenoth DO, Frolich JC: Analysis of cysteine and N-acetylcysteine in human plasma by high-performance liquid chromatography at the basal state and after oral administration of N-acetylcysteine. J Chromatogr B Biomed Sci Appl 708: 55-60, 1998
29. Harada D, Naito S, Kawauchi Y, Ishikawa K, Koshitani O, Hiraoka I, Otagiri M: Determination of reduced, protein-unbound, and total concentrations of N-acetyl-L-cysteine and L-cysteine in rat plasma by postcolumn ligand substitution high-performance liquid chromatography. Anal Biochem 290: 251-259, 2001
30. Thor H, Moldeus P, Orrenius S: Metabolic activation and hepatotoxicity. Effect of cysteine, N-acetylcysteine, and methionine on glutathione biosynthesis and bromobenzene toxicity in isolated rat hepatocytes. Arch Biochem Biophys 192: 405-413, 1979
31. Sjodin K, Nilsson E, Hallberg A, Tunek A: Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol 38: 3981-3985, 1989
32. Uttamsingh V, Keller DA, Anders NM: Acylase I-catalyzed deacetylation of N-acetyl-L-cysteine and S-alkyl-N-acetyl-L-cysteines. Chem Res Toxicol 11: 800-809, 1998
33. Uttamsingh V, Baggs RB, Krenitsky DM, Anders MW: Immunohistochemical localization of the acylases that catalyze the deacetylation of N-acetyl-L-cysteine and haloalkene-derived mercapturates. Drug Metab Dispos 28: 625- 632, 2000
34. Cotgreave IA, Berggren M, Jones TW, Dawson J, Moldeus P: Gastrointestinal metabolism of N-acetylcysteine in the rat, including an assay for sulfite in biological systems. Biopharm Drug Dispos 8: 377-386, 1987
35. Sheffner AL: Metabolic studies with acetylcysteine. Biochem Pharmacol 15: 1523-1535, 1966
36. Burgunder JM, Varriale A, Lauterburg BH: Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 36: 127-131, 1989
37. Cooke MS, Evans MD, Dizdaroglu M, Lunec J: Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J 17: 1195-1214, 2003
38. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr: Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals. Am J Physiol 258: F115-F120, 1990
39. Aruoma OI, Halliwell B, Hoey BM, Butler J: The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6: 593-597, 1989
40. Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R: Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 335: 1572-1573, 1990
41. Reed DJ: Glutathione: Toxicological implications. Annu Rev Pharmacol Toxicol 30: 603-631, 2990
42. Shan XQ, Aw TY, Jones DP: Glutathione-dependent protection against oxidative injury. Pharmacol Ther 47: 61-71, 1990
43. Skrzydlewska E, Farbiszewski R: Protective effect of N-acetylcysteine on reduced glutathione, reduced glutathione-related enzymes and lipid peroxidation in methanol intoxication. Drug Alcohol Depend 57: 61- 67, 1999
44. Nakano H, Boudjema K, Alexandre E, Imbs P, Chenard MP, Wolf P, Cinqualbre J, Jaeck D: Protective effects of N-acetylcysteine on hypothermic ischemia-reperfusion injury of rat liver. Hepatology 22: 539-545, 1995
45. Pastor A, Collado PS, Almar M, Gonzalez-Gallego J: Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteine. J Hepatol 27: 363-370, 1997,
46. Sehirli AO, Sener G, Satiroglu H, Ayanoglu-Dulger G: Protective effect of N-acetylcysteine on renal ischemia/reperfusion injury in the rat. J Nephrol 16: 75-80, 1993
47. Paller MS: Renal work, glutathione and susceptibility to free radical-mediated postischemic injury. Kidney Int 33: 843-849, 1988
48. Scaduto RC, Martin VH: Elevation of renal glutathione enhances ischemic injury. Renal Physiol Biochem 14: 259-270, 1991
49. Salom MG, Ramirez P, Carbonell LF, Conesa EL, Cartagena J, Quesada T, Parrilla P, Fenoy FJ: Protective effect of N-acetyl l-cysteine on the renal failure induced by inferior vena cava occlusion. Transplantation 65: 1315-1321, 1998
50. Girouard H, Chulak C, Wu L, Lejossec M, de Champlain J: N-acetylcysteine improves nitric oxide and alpha-adrenergic pathways in mesenteric beds of spontaneously hypertensive rats. Am J Hypertens 16: 577-584, 2003
51. Loscalzo J: N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 76: 703-708, 1985
52. Boesgaard S, Aldershvile J, Poulsen HE, Christensen S, Dige-Petersen H, Giese J: N-acetylcysteine inhibits angiotensin converting enzyme in vivo. J Pharmacol Exp Ther 265: 1239-1244, 1993
53. Prasad PV, Priatna A, Spokes K, Epstein FH: Changes in intrarenal oxygenation as evaluated by BOLD MRI in a rat kidney model for radiocontrast nephropathy. J Magn Reson Imaging 13: 744-747, 2001
54. Conesa EL, Valero F, Nadal JC, Fenoy FJ, Lopez B, Arregui B, Salom MG: N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol 281: R730-R737, 2001
55. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S: N-acetylcysteine ameliorates renal microcirculation: Studies in rats. Kidney Int 63: 634-641, 2003
56. Levin A, Pate GE, Shalansky S, Al-Shamari A, Webb JG, Buller CE, Humphries KH. N-acetylcysteine reduces urinary albumin excretion following contrast administration: Evidence of biological effect. Nephrol Dial Transplant 22: 2520-2524, 2007
57. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrastagent-induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180-184, 2000
58. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka. JK, Fishbane S: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62: 2202-2207, 2002
59. Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40: 1383-1388, 2002
60. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289: 553-558, 2003
61. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 89: 356-358, 2002
62. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, Sutander A, Williams T, Fox RS, Levin A: A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect. Am Heart J 148: 422-429, 2004
63. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL: N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354: 2773-2782, 2006
64. Yesilbursa D, Serdar A, Senturk T, Serdar Z, Sag S, Cordan J: Effect of N-acetylcysteine on oxidative stress and ventricular function in patients with myocardial infarction. Heart Vessels 21: 33-37, 2006
65. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A: Renal insufficiency following contrast media administration trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation 115: 1211-1217. 2007
66. Birck R, Krzossok S, Makowetz F, Schnulle P, van der Woude F, Braun C: Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 362: 598-603, 2003
67. Isenbarger D, Kent S, O'Malley P: Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 92: 1454-1458, 2003
68. Alonso A, Lau J, Jaber B, Weintraub A, Sarnak M: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am J Kidney Dis 43: 1-9, 2004
69. Kshirsagar A, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, Agrawal M, Denu-Ciocca C, Magnus Ohman E, Finn WF: N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol 15: 761-769, 2004
70. Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65: 1366-1374, 2004
71. Guru V, Fremes S: The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 62: 77-83, 2004
72. Bagshaw S, Ghali WA: Acetylcysteine for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. BMC Med 2: 38, 2004
73. Misra D, Leibowitz K, Gowda R, Shapiro M, Khan J: Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 27: 607-610, 2004
74. Nallamothu. BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER: Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 117: 938-947, 2004
75. Liu R, Nair D, Ix J, Moore D, Bent S: N-acetylcysteine for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. J Gen Intern Med 20: 193-200, 2005
76. Duong M, MacKenzie T, Malenka D: N-Acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 64: 471-479, 2005
77. Bagshaw SM, McAlister FA, Marms BJ, Ghali WA: Acetylcysteine in the prevention of contrast-induced nephropathy: A case study of the pitfalls in the evolution of evidence. Arch Intern Med 166: 161-166, 2006
78. Vaitkus PT, Brar C: N-acetylcysteine in the prevention of contrast-induced nephropathy: Publication bias perpetuated by meta-analyses. Am Heart J 153: 275-280, 2007
79. Izzedine H, Guerin V, Launay-Vacher V, Bernard M, Deray G: Effect of N-acetylcysteine on serum creatinine level. Nephrol Dial Transplant 16: 1514-1515, 2001
80. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15: 407-410, 2004